Form 8-K - Current report:
SEC Accession No. 0001437749-22-003966
Filing Date
2022-02-22
Accepted
2022-02-22 09:13:37
Documents
15
Period of Report
2022-02-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cbli20220222_8k.htm   iXBRL 8-K 26048
2 EXHIBIT 99.1 ex_338834.htm EX-99.1 15297
7 logo01.jpg GRAPHIC 12153
  Complete submission text file 0001437749-22-003966.txt   195113

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stab-20220222.xsd EX-101.SCH 3602
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stab-20220222_def.xml EX-101.DEF 11533
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE stab-20220222_lab.xml EX-101.LAB 15415
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stab-20220222_pre.xml EX-101.PRE 11689
9 EXTRACTED XBRL INSTANCE DOCUMENT cbli20220222_8k_htm.xml XML 2560
Mailing Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526
Business Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526 (888) 613-8802
Statera Biopharma, Inc. (Filer) CIK: 0001318641 (see all company filings)

EIN.: 200077155 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32954 | Film No.: 22655461
SIC: 2834 Pharmaceutical Preparations